Tag: AQST-109
Aquestive’s Sublingual Emergency Epinephrine Compares Favorably to EpiPen® in EPIPHAST II...
The company announced topline results from their EPIPHAST II study.
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
Phase 2 study continues to show AQST-109 is safe and well tolerated.
They’re Coming: Needle-Free Emergency Epinephrine Options Currently in Trials
For some, the needle is a barrier to administration but alternatives are on the horizon.
Stealth Mode Company Granted Patent for Sublingual Epinephrine Tablet
We've been reporting on the progress of AQST-109 by Aquestive Therapeutics, a postage-stamp-sized film placed under the tongue that provides epinephrine in an anaphylactic...
Sublingual Epinephrine for Anaphylaxis Receives Fast Track Designation from FDA
AQST-109 is the first orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions including anaphylaxis.
CEO Expects Approval and Launch of Intranasal Emergency Epinephrine Spray by...
The market for epinephrine delivery may expand to include non-needle alternatives next year.
Aquestive’s Sublingual Epinephrine Achieves Therapeutic Blood Concentrations Following Administration
Company presented top level Phase 1 results at #AAAAI2022 meeting.
Sublingual Emergency Epinephrine Takes Another Step Forward in Phase 1 Study
Aquestive's postage-stamp-sized film is designed to dissolve under the tongue to provide epinephrine.
